Trials / Unknown
UnknownNCT06258629
Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
Resident of Clinical Pathology in Sohag Oncology Center
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Sohag University · Academic / Other
- Sex
- All
- Age
- 1 Year – 60 Years
- Healthy volunteers
- —
Summary
Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Flowcytometry on bone marrow aspiration | Flowcytometry on bone marrow aspiration |
Timeline
- Start date
- 2024-02-15
- Primary completion
- 2025-02-06
- Completion
- 2025-02-06
- First posted
- 2024-02-14
- Last updated
- 2024-02-14
Source: ClinicalTrials.gov record NCT06258629. Inclusion in this directory is not an endorsement.